Dianthus Therapeutics, Inc.
107.04USD
-2.0900 (-1.92%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $-0.95▲ | $-1.02 | 2 | 1 |
| Next quarter | $-1.13▲ | $-1.18 | 2 | 1 |
| Current year | $-3.83▲ | $-3.93 | 2 | 1 |
| Next year | $-4.62▲ | $-4.65 | 2 | 1 |
Beat in 2 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $-0.91 | $-0.9 | +0.01 (+1.0%) |
| 2026-03-31 | $-1.1 | $-0.85 | +0.25 (+22.9%) |
| 2025-12-31 | $-1.03 | $-1.43 | -0.40 (-38.6%) |
| 2025-09-30 | $-0.9 | $-0.97 | -0.07 (-7.9%) |
59 ratings from 17 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Citigroup | Initiated | Buy | $156 | Sep 4, 2026 |
| Truist Securities | Maintained | Buy | $110 $128 | Aug 6, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $130 $158 | Aug 6, 2026 |
| Wedbush | Maintained | Outperform | $105 $122 | Aug 5, 2026 |
| Evercore ISI Group | Maintained | Outperform | $120 $134 | Aug 3, 2026 |
| Wedbush | Maintained | Outperform | $103 $105 | May 6, 2026 |
| Wolfe Research | Initiated | Outperform | $98 | Apr 9, 2026 |
| Wells Fargo | Initiated | Overweight | $135 | Mar 19, 2026 |
| Wedbush | Maintained | Outperform | $80 $103 | Mar 12, 2026 |
| Wedbush | Maintained | Outperform | $55 $80 | Mar 10, 2026 |
| Raymond James | Upgraded from Outperform | Strong Buy | $63 $123 | Mar 10, 2026 |
| Baird | Maintained | Outperform | $67 $132 | Mar 10, 2026 |
| Clear Street | Maintained | Buy | $100 $130 | Mar 10, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $47 $130 | Mar 9, 2026 |
| Oppenheimer | Maintained | Outperform | $125 $145 | Mar 9, 2026 |
| Truist Securities | Maintained | Buy | $63 $110 | Mar 9, 2026 |
| Guggenheim | Maintained | Buy | $100 $200 | Mar 4, 2026 |
| Wedbush | Maintained | Outperform | $46 $55 | Feb 11, 2026 |
| Jefferies | Maintained | Buy | $66 $81 | Feb 2, 2026 |
| Truist Securities | Maintained | Buy | $56 $63 | Jan 8, 2026 |
| Wedbush | Reiterated | Outperform | $46 | Dec 22, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $40 $47 | Nov 10, 2025 |
| Wedbush | Maintained | Outperform | $44 $46 | Nov 6, 2025 |
| Truist Securities | Initiated | Buy | $56 | Oct 14, 2025 |
| Clear Street | Initiated | Buy | $100 | Sep 17, 2025 |
49 filings from 9 insiders · 19 buy / 17 sell over 6m
Officers and directors of DNTH, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Randhawa SimratOfficer, EVP, Head of R&D | ExerciseStock Option (Right to Buy) | 9.4k | — | — | Sep 1, 2026 |
| Randhawa SimratOfficer, EVP, Head of R&D | ExerciseStock Option (Right to Buy) | 6.2k | — | — | Sep 1, 2026 |
| Randhawa SimratOfficer, EVP, Head of R&D | ExerciseStock Option (Right to Buy) | 7.5k | — | — | Sep 1, 2026 |
| Randhawa SimratOfficer, EVP, Head of R&D | Sell | 13.3k | $106.74 | $1.42M | Sep 1, 2026 |
| Randhawa SimratOfficer, EVP, Head of R&D | Sell | 7.2k | $106.25 | $767k | Sep 1, 2026 |
| Randhawa SimratOfficer, EVP, Head of R&D | Sell | 2.6k | $105.19 | $273k | Sep 1, 2026 |
| Randhawa SimratOfficer, EVP, Head of R&D | Exercise | 9.4k | $22.07 | $207k | Sep 1, 2026 |
| Randhawa SimratOfficer, EVP, Head of R&D | Exercise | 6.2k | $21.77 | $136k | Sep 1, 2026 |
| Randhawa SimratOfficer, EVP, Head of R&D | Exercise | 7.5k | $17.88 | $134k | Sep 1, 2026 |
| READ SIMON J.Director | Exercise | 2.8k | $18.36 | $51k | Aug 19, 2026 |
| READ SIMON J.Director | Sell | 2.8k | $117.55 | $327k | Aug 19, 2026 |
| VENESS ADAM MGeneral Counsel | Exercise | 15.0k | $18.17 | $273k | Aug 13, 2026 |
| READ SIMON J.Director | Exercise | 2.8k | $18.36 | $51k | Aug 10, 2026 |
| VENESS ADAM MGeneral Counsel | Exercise | 20.0k | $17.88 | $358k | Aug 10, 2026 |
| MCGEORGE ANNEDirector | Exercise | 7.8k | $11.20 | $97k | Aug 10, 2026 |
| READ SIMON J.Director | Sell | 2.8k | $107.11 | $304k | Aug 10, 2026 |
| VENESS ADAM MGeneral Counsel | Sell | 20.0k | $110.38 | $2.21M | Aug 10, 2026 |
| MCGEORGE ANNEDirector | Sell | 7.8k | $107.58 | $845k | Aug 10, 2026 |
| GARCIA MARINOChief Executive Officer | Exercise | 166.0k | $8.44 | $1.40M | Aug 7, 2026 |
| GARCIA MARINOChief Executive Officer | Sell | 166.0k | $107.49 | $17.95M | Aug 7, 2026 |
No analyst notes on DNTH yet.
Analyst Ratings
14 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 0 | 15 | 0 | 0 | 0 | Buy2.00 |
| 1 mo ago | 0 | 14 | 0 | 0 | 0 | Buy2.00 |
| 2 mo ago | 0 | 15 | 0 | 0 | 0 | Buy2.00 |
| 3 mo ago | 0 | 15 | 0 | 0 | 0 | Buy2.00 |